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Background: Metformin, a standard therapy in type 2 diabetes, reduces vitamin B12 levels. Studies linking low
vitamin B12 levels and cardiovascular disease are equivocal and suggest improving B12 levels may help in primary
prevention. The role of vitamin B12 deficiency on cardiovascular risk factors, especially in type 2 diabetes has not
been explored. The aim of this study is to investigate whether vitamin B12 deficiency in type 2 diabetes patients is
associated with cardiovascular risk factors in two different ethnic groups in UK and India.
Methods: Type 2 diabetes patients from two secondary care diabetic centres (Europeans - UK and Indians - India)
were studied. Serum vitamin B12, folate and biochemical parameters were measured.
Results: The prevalence rates of vitamin B12 deficiency (<191 ng/L) were 27% and 12% in Europeans and Indians,
respectively and higher in metformin treated type 2 diabetes patients. In linear regression analysis, after adjusting
for all likely confounding factors, vitamin B12 independently associated with triglycerides in both the populations
and cholesterol/HDL ratio in Indians. Logistic regression showed type 2 diabetes patients with vitamin B12
deficiency were at significantly higher odds of having coexisting coronary artery disease (CAD) in Europeans with
similar but non-significant trend in Indians, after adjusting for all likely confounding factors.
Conclusions: The prevalence of vitamin B12 deficiency is common in type 2 diabetes patients and is associated
with adverse lipid parameters. Type 2 diabetes management guidelines should include the recommendation for
regular testing for B12 levels, especially for those on metformin.Introduction
Vitamin B12 is a key micronutrient responsible for DNA
methylation and has various metabolic roles ranging from
lipid metabolism to endothelial dysfunction [1]. Studies
show association of low vitamin B12 with macro-vascular
diseases such as myocardial infarction [2] and cerebral is-
chemia [3] as well as coronary artery disease (CAD) [4].
However, a systematic review of all published cohort stud-
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article, unless otherwise stated.vascular complications such as neuropathy [6] and can
worsen the existing neuropathy due to other conditions
such as diabetes [7].
Metformin therapy is now considered a standard first
line therapy for type 2 diabetes (ADA, NICE, EASD
guidelines) [8,9] and is commonly used. Metformin re-
duces the circulating B12 levels by about 25% [10-12].
One cross-sectional study of 203 type 2 diabetes patients
reported the prevalence of B12 deficiency is 22% [13].
However, only 60% of patients with B12 deficiency have
anaemia [14] and at milder forms patients with B12 defi-
ciency are asymptomatic. This highlights the importance
of regular screening but none of the above mentioned
guidelines recommend measuring B12 levels regularly in
type 2 diabetes, even when they are on metformin.ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Adaikalakoteswari et al. Cardiovascular Diabetology 2014, 13:129 Page 2 of 7
http://www.cardiab.com/content/13/1/129Indians have higher risk of metabolic disorders includ-
ing type 2 diabetes and cardiovascular diseases (CVD)
compared to Europeans [15,16] and these diseases also
occur at younger age [17]. They also have higher homo-
cysteine levels, which have been mainly attributed to low
B12 levels [18]. Vegetarianism is thought to be cause of
such high prevalence of B12 deficiency in this popula-
tion. Whether high prevalence of B12 deficiency contrib-
utes to higher risk of CVD is not known [19].
The purpose of our study is (1) to assess the preva-
lence of vitamin B12 deficiency in type 2 diabetes pa-
tients and (2) its association with cardiovascular risk
factors and micro- and macro-vascular diseases in two
different ethnic groups in UK and India.
Methods
Study population
Cross-sectional data from two different secondary care
diabetic centres were utilized for this study. (1) UK
participants: 342 consecutive patients of European ori-
gin with type 2 diabetes, who had their vitamin B12
and folate levels checked in the George Eliot Hospital
(GEH), Nuneaton, UK. (2) Indian participants: 321
type 2 diabetes patients of Indian origin had their vita-
min B12 checked at the Dr Mohan’s Diabetes Special-
ties Centre were included for the analysis. Patients who
were taking vitamin supplements and who were preg-
nant were excluded from the study. Detailed history,
anthropometric and biochemical measures such as age,
sex, type of diabetes, duration of diabetes, HbA1C, smok-
ing status, medications, blood pressure, micro- and
macro-vascular complications of diabetes, lipid profile,
vitamin B12 and folate levels were collected from both the
study population. Information on dietary intake (vegetar-
ian/non-vegetarian) was not collected. These were routine
anonymous clinical data extracted from records.
Analytical determinations
Serum glucose, HbA1C, cholesterol, triglycerides, HDL
cholesterol were determined by standard methodologies
followed in the respective labs in both the study popula-
tion. LDL cholesterol was calculated using Friedewald
formula. Serum B12 and folate were determined by elec-
trochemiluminescent immunoassay using a Roche Cobas
immunoassay analyzer (Roche Diagnostics UK, Burgess
Hill, UK). The reference values in both the laboratories
were as follows: 191–663 ng/L for vitamin B12 and 2.5-
18.7 ug/L for folate. Vitamin B12 and folate deficiencies
were defined as levels below 191 ng/L [20] and 2.5 μg/L
[21], respectively.
Definition of comorbidity
The following definitions were used to diagnose the co-
morbidity. Retinopathy: Digital retinal photographs weregraded by trained ophthalmologists (India) or retinal
graders (UK) by the ETDRS grading system. Neuropathy:
Vibratory perception threshold of the great toe > mean +
2SD of healthy non-diabetic study population aged 20–45
years (cut point ≥20 V). Nephropathy: Albumin excre-
tion ≥30 μg/mg of creatinine in urine sample after an
overnight fast (microalbuminuria - 30–299 μg/mg of
creatinine and macroalbuminuria - ≥300 μg/mg of cre-
atinine). Patients with documented retinopathy, periph-
eral and autonomic neuropathy, and nephropathy were
recorded individually and classified to have microvascu-
lar complications. Coronary artery disease (CAD): Past
history of documented myocardial infarction, stable and
unstable angina, coronary artery bypass graft, stent
and/or electrocardiographic changes suggestive of ST
segment depression and/or Q-wave changes using ap-
propriate Minnesota codes. Cerebrovascular accidents
(CVA): Past history of documented stroke (computed
tomography, magnetic resonance imaging, or cerebral
angiography). Peripheral vascular disease (PVD): Lack
of peripheral pulses or Doppler studies with Ankle Bra-
chial Index <0.9. Those with documented CAD, CVA
and PVD were recorded individually and classified to
have macrovascular complications.
Statistical analysis
Continuous variables are reported as mean ± standard
deviation (SD). Categorical variables are reported in per-
centages. The distributions of the parameters such as
cholesterol, triglycerides, HDL, LDL, vitamin B12 concen-
trations were skewed; these data were log-transformed.
Means of continuous variables were compared using inde-
pendent t-tests. Bivariate correlations between different
variables were done using Pearson correlation test. Risk
variables that had significant association were included as
independent variables in multiple linear regression ana-
lysis. Logistic regression analysis was used to examine the
relation between vitamin B12 levels and the risk of micro-
and macro-vascular complications. Associations between
vitamin B12 and cardiovascular outcomes were adjusted
for age, gender, BMI, duration of diabetes, smoking,
HbA1C, cholesterol, HDL, triglycerides, systolic and
diastolic pressure, use of metformin, statin and aspirin.
p values of <0.05 were considered as statistically signifi-
cant. All analyses were performed using IBM SPSS Sta-
tistics version 19 (IBM Corp, NY, USA).
Results
The clinical characteristics of the study population are
shown in Table 1. The use of metformin in Europeans
was 65% and in Indians is 75%. The prevalence rates of
serum vitamin B12 deficiency (<191 ng/L) in Europeans
were 27% and Indians were 12% (Table 1). For those on
metformin, these rates were 32.1 and 12.4%, respectively.
Table 1 Basic Characteristics of the study population
Parameters Europeans Indians
total total
n = 342 n = 321
Age (years) 63.0 ± 12.3a 56.8 ± 10.6
BMI (Kg/m2) 32.8 ± 6.1 28.0 ± 5.7
Duration of diabetes (years) 14.1 ± 9.4 8.4 ± 7.6
HbA1C (%) 7.89 ± 1.62 8.30 ± 2.1
Cholesterol (mmol/L) 4.10 ± 1.10 4.0 ± 1.12
Triglycerides (mmol/L) 2.01 ± 1.48 1.77 ± 0.89
HDL (mmol/L) 1.25 ± 0.35 0.98 ± 0.25
LDL (mmol/L) 1.97 ± 0.81 2.20 ± 0.91
Cholesterol/HDL ratio 3.46 ± 1.19 4.18 ± 1.16
SBP (mmHg) 137 ± 20 132 ± 18
DBP (mmHg) 74 ± 11 81 ± 9.3
Vitamin B12 (ng/L) 290 ± 139 464 ± 228
Vitamin B12 deficiency, n (%) 91 (27)b 37 (12)
Folate (ug/L) 7.71 ± 9.77 13.6 ± 5.2
Folate deficiency, n (%) 29 (8.5) 0
Smoking, n (%) 26 (8.5) 75 (24)
Microvascular complications:
Retinopathy, n (%) 124 (36) 132 (45)
Neuropathy, n (%) 53 (16) 99 (33)
Nephropathy, n (%) 41 (12) 83 (29)
Macrovasuclar complications:
Coronary artery disease (CAD), n (%) 62 (18) 27 (9)
Cerebro vascular accidents (CVA), n (%) 19 (5.6) 6 (1.9)
Peripheral vascular disease (PVD), n (%) 23 (6.7) 17 (6)
Insulin use, n (%) 215 (63) 149 (46)
Metformin use, n (%) 221 (65) 242 (75)
Statin use, n (%) 286 (84) 154 (48)
Aspirin use, n (%) 246 (72) 44 (14)
aMean ± SD (all such values); bNumbers (percentages) (all such values).
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folic acid (Additional file 1: Table S1). The sex specific
values of the other variables are also shown in the
Additional file 1: Table S1. In both the populations, tri-
glycerides and cholesterol/HDL ratio were significantly
and inversely associated with vitamin B12 levels. HDL
was positively associated with vitamin B12 levels in
Europeans but cholesterol was not significantly associated
with vitamin B12 in both the populations (Additional file 1:
Table S2). No associations of vitamin B12 with other estab-
lished cardiovascular risk factors such as BMI, systolic and
diastolic pressure and HbA1C were observed (data not
shown).
Linear regression analysis was carried out to assess
whether vitamin B12 independently associated withthese cardiovascular risk factors in the type 2 diabetes
patients by adjusting for all likely confounders. The
model included age, gender, BMI, duration of diabetes,
smoking, HbA1C, use of metformin, statin and aspirin as
independent variables. After all these adjustments, vita-
min B12 independently associated with triglycerides in
both the populations (Figure 1a,b) but cholesterol/HDL
ratio only in Indians (Figure 1d).
Association of vitamin B12 levels and individual co-
morbidities were assessed by logistic regression analysis
(Table 2). After adjustment for age, gender, BMI, dur-
ation of diabetes, smoking, HbA1C, cholesterol, HDL,
LDL, triglycerides, systolic and diastolic pressure, use of
metformin, statin and aspirin, type 2 diabetes patients
with low vitamin B12 levels were at a significantly higher
odds of having coexisting CAD in Europeans (OR =
3.91; 95% CI: 1.09 - 14.05). A similar but non-significant
trend of higher risk was observed in Indians (OR = 1.77;
95% CI: 0.376 - 8.33). No associations with other micro-
or macro- vascular diseases were observed.
Discussion
Our study involving two different ethnic groups with
type 2 diabetes patients had three main findings. Firstly,
there was high prevalence of vitamin B12 deficiency in
Europeans but interestingly lower than observed preva-
lence in Indians from South India. Secondly, vitamin
B12 deficiency was associated with adverse lipid profiles.
Thirdly, low vitamin B12 levels in type 2 diabetes pa-
tients were associated with an increased risk of CAD.
Studies in type 2 diabetes patients of European origin
on metformin have reported the prevalence of vitamin
B12 deficiency to range from 5.8% to 33% [10,11,13,22].
Our study confirms this in the British population, with a
prevalence of 27% in all type 2 diabetes and 32.1% in
type 2 diabetes with metformin. Our study is the first
one to report the prevalence of B12 deficiency in the
South Indian population with type 2 diabetes. Previous
studies in north Indian population showed much higher
rates of 67% in middle-aged men [18] and 54% in dia-
betes patients [23]. This is likely due to the differences
in dietary habits between north and south Indians. South
Indians consume higher quantity of fermented foods,
which are rich in vitamin B12 [24,25].
In this study, vitamin B12 deficiency independently as-
sociated with triglycerides and cholesterol/HDL ratio in
type 2 diabetes patients. Our findings were similar to the
study in Indians with history of CAD [4]. Similar corre-
lations were also found between B12 levels and total
cholesterol and triglycerides in a group of Polish patients
with established atherosclerosis, but this relationship
was lost in regression analysis, which may be due to the
smaller sample size in the study [21]. Vitamin B12 func-
tions as a coenzyme in the conversion of methylmalonyl-
Figure 1 Regression of Vitamin B12 with (a) Triglycerides in Europeans, (b) Triglycerides in Indians, (c) Cholesterol: HDL ratio in
Europeans and (d) Cholesterol: HDL ratio in Indians. *Log-transformed for statistical comparisons. Model included vitamin B12, age, BMI, sex,
duration of diabetes, HbA1C, smoking, use of metformin, statin & aspirin.
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blocked if there is vitamin B12 deficiency, resulting in ac-
cumulation of MM-CoA which inhibits the rate-limiting
enzyme of fatty acid oxidation (CPT1 – carnitine palmi-
toyl transferase) [28], thus causing lipogenesis. This mayTable 2 Logistic regression analysis of vitamin B12 with co-m
Co-morbidities Europeans
B (SE) Odds ratio (95% C
Microvascular complications:
Retinopathy 0.294 (0.604) 1.342 (0.411, 4.386)
Neuropathy 0.132 (0.663) 1.141 (0.311, 4.186)
Nephropathy 0.790 (1.132) 2.203 (0.239, 20.267
Macrovascular complications:
Coronary artery disease (CAD) 1.364 (0.653) 3.911 (1.088, 14.054
Cerebro vascular accidents (CVA) −1.226 (1.508) 0.294 (0.015, 5.644)
Peripheral vascular disease (PVD) 0.552 (0.608) 1.737 (0.527, 5.722)
Model included vitamin B12, age, BMI, sex, duration of diabetes, HbA1C, Cholestero
and aspirin.
*- Odds ratio cannot be computed because in the PVD group, the number of B12 dbe the likely mechanism for the link between B12 defi-
ciency and adverse lipid parameters.
Our observation of an association of increased risk of
CAD in type 2 diabetes patients with low B12 levels after
controlling for all likely confounding factors is supportedorbidities
Indians
I) p-value B (SE) Odds ratio (95% CI) p-value
0.626 −0.085 (0.440) 0.919 (0.388, 2.176) 0.848
0.842 −0.208 (0.558) 0.812 (0.272, 2.424) 0.709
) 0.485 −0.721 (0.519) 0.487 (0.176, 1.346) 0.165
) 0.037 0.571 (0.790) 1.770 (0.376, 8.332) 0.470
0.416 0.775 (1.584) 2.170 (0.097, 48.369) 0.625
0.364 - -* -
l, HDL, LDL, triglycerides, SBP, DBP, smoking, use of metformin, statin
eficient cases were zero.
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non-type 2 diabetes. A study by Shargorodsky et al.
found that vitamin B12 independently correlated with
pulse wave velocity in type 2 diabetes patients, an ac-
cepted cardiovascular risk factor [29]. Weikert et al. [3]
in a population-based prospective study showed the as-
sociation between low vitamin B12 levels and increased
risk of cerebral ischemia. Similarly, in south Asian
women living in the UK with vitamin B12 deficiency an-
aemia had a higher prevalence of myocardial infarction
and CAD [30]. We did not find any sex specific changes
in our study. Thus our findings in support of the previ-
ous observations extend the knowledge on the role of
vitamin B12 on CAD and its risk factors in type 2 dia-
betes patients. In spite of the fact that B-vitamins could
provide an inexpensive and effective method for the pre-
vention of CVD, their use was rejected, based on the
negative results of randomized controlled clinical trials
[31,32]. But, when examining the design of these trials,
it appeared that concomitant medication such as statin/
aspirin therapy applied along with the vitamin substitu-
tion could have obscured the separate effects of vitamins
in cardiovascular prevention. However, a recent meta-
analysis of these vitamin trials suggest that B vitamins
are effective in primary prevention of cardiovascular dis-
eases [33]. Similarly, a study in type 2 diabetes patients
with another micronutrient supplementation, vitamin D,
showed more significant improvements in the cardio-
metabolic profile [34].
Lipid abnormalities are unique in individuals with T2D
and those are at risk of T2D (obesity, metabolic syn-
drome and pre-diabetes): the total cholesterol and LDL
are lower in those with statins but higher in those with-
out. In addition, in both groups the triglyceride levels
are higher and the HDL levels are lower as statins have
little effect on them [35-37]. In post-menopausal women
with T2D and CAD who were not on lipid lowering
medications, in addition to higher total and LDL choles-
terol and higher triglycerides, homocysteine was also
higher, suggesting a potential link between vitamin B12
and folic acid and abnormal lipid profiles [38-41]. It is
known that increasing triglycerides and reducing HDL
are early features of atherosclerosis, well before increas-
ing LDL [38,42]. Therefore, our findings showing inde-
pendent association of B12 with triglycerides and HDL
in two different ethnic groups provide a possible mech-
anism how vitamin B12 could offer primary prevention
of cardiovascular diseases in type 2 diabetes and may
also be an option in the secondary prevention of disease,
if statin therapy is accompanied by serious adverse
effects.
The strength of this study is the inclusion of two
cross-sectional study populations of type 2 diabetes pa-
tients from UK and India and comprehensive data fromboth the groups. However, it also has the following limi-
tations. The study population were based in secondary
care and not a true representative sample of all type 2
diabetes. A true primary care representative sampling of
type 2 diabetes would have strengthened our findings.
However, metformin is routinely prescribed in primary
care. This therefore might have under estimated the
prevalence of B12 deficiency and may have overesti-
mated its association with CAD as the prevalence of
CAD is likely to be higher in secondary care settings. A
group of Indian diaspora living in the UK as well as the
availability of biomarkers of vitamin B12 deficiency such
as MMA and homocysteine would have strengthened
the findings. In addition, being a cross-sectional study, it
does not prove causality.
In summary, our study demonstrates for the first time
that vitamin B12 deficiency in type 2 diabetes patients in
two different ethnic groups is associated with adverse
lipid parameters and higher risk of CAD. Currently,
there are no guidelines advocating for routine screening
for vitamin B12 deficiency among patients with type 2
diabetes. While optimal screening frequency remains to
be determined, baseline tests at initiation of metformin
therapy and subsequent annual testing of B12 levels may
be appropriate. Our study also warrants updating of
international guidelines for the management of type 2
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